Share on StockTwits

An executive vice-president of Valeant Pharmaceuticals International Inc will leave the company, even as the Canadian drugmaker fends off criticism about management turnover from its takeover target Allergan Inc . Valeant confirmed late on Friday after inquiries by Reuters, Executive vice-president and company group chairman Ryan Weldon will leave. Like Chief Executive Mike Pearson, Weldon previously worked for management consulting firm McKinsey & Co. Valeant said Weldon’s departure was planned, and takes effect after it completes a $1.4 billion sale of several injectable treatments to Nestle SA .



“Valeant Senior Official Leaves Amid Allergan Takeover Battle” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.